Table 3.
Variables | GLUT-1 Low n = 24 (48.0%) |
GLUT-1 High n = 26 (52.0%) |
Univariable P* |
---|---|---|---|
Clinical factors | |||
Sex | |||
Male/female | 13/11 | 16/10 | 0.775 |
Age (years) | 68 (32 − 83) | 70 (46 − 81) | 0.303 |
CEA (ng/mL) | 2.8 (0.4 − 8.8) | 3.6 (0.7 − 133.1) | 0.265 |
CA19-9 (IU/mL) | 38.7 (0.7 − 766) | 65.5 (0.8 − 3055) | 0.593 |
SUVmax | 4.5 (2.9 − 9.2) | 7.0 (3.6 − 14.7) | < 0.001 |
MTV (cm3) | 8.4 (1.5 − 604.0) | 72.0 (3.6 − 777.0) | 0.008 |
TLG (g) | 20.2 (3.6 − 3201.2) | 259.2 (27.0 − 3418.8) | < 0.001 |
Tumor size (cm) | |||
Radiographical | 3.5 (1.0 − 11.0) | 4.0 (1.0 − 14.0) | 0.108 |
Treatment factors | |||
R0 resection, n (%) | 23 (95.8) | 25 (96.2) | 1.000 |
Minor hepatectomy, n (%) | 4 (16.7) | 2 (7.7) | 0.409 |
Morbidity | |||
C-D class III/IV, n (%) | 5 (20.8) | 7 (26.9) | 0.745 |
Preoperative chemotherapy | |||
Present, n (%) | 0 | 0 | 0 |
Adjuvant chemotherapy | |||
Present, n (%) | 17 (70.8) | 13 (50.0) | 0.159 |
Pathological factors | |||
Tumor differentiation | |||
Well/moderate, n (%) | 22 (91.7) | 21 (80.8) | 0.420 |
Poor, n (%) | 2 (8.3) | 5 (19.2) | |
Vascular invasion | |||
Present, n (%) | 18 (75.0) | 16 (61.5) | 0.372 |
Bile duct invasion | |||
Present, n (%) | 11 (45.8) | 13 (50.0) | 0.785 |
Lymph node metastasis | |||
Present, n (%) | 7 (29.2) | 8 (30.8) | 1.000 |
Tumor number | |||
Multiple, n (%) | 2 (8.3) | 13 (50.0) | 0.002 |
Tumor size (cm) (pathological) | 3.2 (1.0 − 10.8) | 4.0 (1.2 − 14.0) | 0.073 |
AJCC stage | |||
IV, n (%) | 8 (33.3) | 17 (65.4) | 0.047 |
AJCC American joint committee on cancer/international union against cancer classification, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, MTV metabolic tumor volume, SUVmax maximum standardized uptake value, GLUT-1 glucose transporter-1, R0 resection no macroscopic and microscopic tumor remaining, C-D, Clavien-Dindo classification system
*Statistically significant differences (P < 0.05) are shown in italic